Working Group Drug-Development and Healthcare

Members of the Department of Clinical Pharmacology are involved in national and international committees and advisory boards to transfer knowledge.

Delegation of experts to the European Medicines Agency – EMA

• Committe for Orphan Medicinal Products (COMP): Brigitte Blöchl-Daum previously Bernd Jilma and Hans-Georg Eichler
   
• Committee for Advanced Therapies (CAT): Martin Brunner, previously Bernd Jilma
   
• Scientific Advice Working Party (SAWP): Brigitte Blöchl-Daum, previously Bernd Jilma and Hans-Georg Eichler
   
• Additional EMA-Experts: Rosemarie Bauer, Bernd Jilma, Robert Sauermann, Michael Wolzt, Markus Zeitlinger

Committee on Reimbursement of Drugs of the Austrian Sick Funds and Social Security Association Institutions (Heilmittelevaluierungkommission – HEK)

Chair: Markus Müller, Vice-Chair: Brigitte Blöchl-Daum
 

Scientific Committee of the Medicinal Products Advisory Council - Austrian Ministry of Health

Brigitte Blöchl-Daum, Martin Brunner, Bernd Jilma, Markus Müller, Michael Wolzt, Markus Zeitlinger

Ethics Committee of the Medical University of Vienna

Brigitte Blöchl-Daum, Martin Brunner, Michael Wolzt, Markus Zeitlinger

Key Publications

1. Hans-Georg Eichler, Lynn G Baird, Richard Barker, Brigitte Bloechl-Daum et al. From adaptive licensing to adaptive pathways: Delivering a flexible life-span approach to bring new drugs to patients. CLINICAL PHARMACOLOGY & THERAPEUTICS Volume 97,3, 234–246, (2015) DOI: 10.1002/cpt.59
    
2. Eichler HG*, Bloechl-Daum Brigitte*, Brasseur D, Breckenridge A, Leufkens H, Raine J, Salmonson T, Schneider CK, Rasi G. : The risks of risk aversion in drug regulation. Nat Rev Drug Discov. 2013 Dec;12(12):907-16.
    *Contributed equally to this work, corresponding author
    
3. Eichler HG, Abadie E, Breckenridge A, Flamion B, Gustafsson LL, Leufkens H, Rowland M, Schneider CK, Bloechl-Daum B*: Bridging the efficacy–effectiveness gap: a regulator’s perspective on addressing variability of drug response: NATURE REVIEWS  DRUG DISCOVERY Volume 10, July 2011, 495-506
   *Corresponding Author
    
4.  The Committee for Orphan Medicinal Products and the European Medicines Agency Scientific Secretariat:  Outlook: European regulation on orphan medicinal products: 10 years of experience and future perspectives. European regulation on orphan medicinal products: 10 years of experience and future perspectives.: Westermark K, Holm BB, Söderholm M, Llinares-Garcia J, Rivière F, Aarum S, Butlen-Ducuing F, Tsigkos S, Wilk-Kachlicka A, N'Diamoi C, Borvendég J, Lyons D, Sepodes B, Bloechl-Daum B, et al. NATURE REVIEWS DRUG DISCOVERY 10, 341-349 (May 2011) | doi:10.1038/nrd3445
    

5.      Eichler HG, Bloechl-Daum B*, Abadie E, Barnett D, König F, Pearson S: Relative efficacy of drugs: an emerging issue between regulatory agencies and third-party payers. NATURE REVIEWS DRUG DISCOVERY 9, (April 2010) 277-291
*Corresponding Author and Shared First Author